Somewhat Favorable Press Coverage Somewhat Unlikely to Impact Catalent (CTLT) Stock Price

Headlines about Catalent (NYSE:CTLT) have trended somewhat positive recently, Accern Sentiment reports. The research firm identifies negative and positive press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Catalent earned a coverage optimism score of 0.09 on Accern’s scale. Accern also assigned news stories about the company an impact score of 46.8107996936075 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

These are some of the media headlines that may have effected Accern’s scoring:

How to Become a New Pot Stock Millionaire

Shares of NYSE CTLT opened at $41.40 on Thursday. The company has a market capitalization of $5,623.38, a P/E ratio of 30.67, a price-to-earnings-growth ratio of 2.30 and a beta of 1.53. Catalent has a 1 year low of $28.76 and a 1 year high of $47.87. The company has a debt-to-equity ratio of 2.66, a current ratio of 2.22 and a quick ratio of 1.78.

Catalent (NYSE:CTLT) last issued its quarterly earnings data on Monday, February 5th. The company reported $0.41 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.31 by $0.10. The business had revenue of $606.30 million during the quarter, compared to analyst estimates of $565.05 million. Catalent had a net margin of 3.03% and a return on equity of 23.85%. The firm’s quarterly revenue was up 25.3% on a year-over-year basis. During the same quarter last year, the business earned $0.27 EPS. analysts forecast that Catalent will post 1.52 earnings per share for the current fiscal year.

A number of research firms have recently commented on CTLT. Goldman Sachs began coverage on shares of Catalent in a report on Wednesday, January 24th. They issued a “buy” rating and a $50.00 target price for the company. Royal Bank of Canada set a $48.00 target price on shares of Catalent and gave the stock a “buy” rating in a report on Monday, February 5th. Stephens cut shares of Catalent from an “overweight” rating to an “equal weight” rating in a report on Tuesday, February 6th. Zacks Investment Research raised shares of Catalent from a “hold” rating to a “buy” rating and set a $48.00 target price for the company in a report on Wednesday, January 17th. Finally, Bank of America increased their target price on shares of Catalent from $47.00 to $49.00 and gave the stock a “buy” rating in a report on Tuesday, February 6th. Five analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $45.75.

In other Catalent news, SVP William Downie sold 9,082 shares of the firm’s stock in a transaction that occurred on Thursday, March 8th. The shares were sold at an average price of $41.80, for a total transaction of $379,627.60. Following the completion of the transaction, the senior vice president now owns 46,986 shares in the company, valued at approximately $1,964,014.80. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 1.70% of the stock is owned by company insiders.

COPYRIGHT VIOLATION WARNING: This article was originally published by Week Herald and is the sole property of of Week Herald. If you are accessing this article on another site, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The original version of this article can be viewed at

Catalent Company Profile

Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through three segments: Softgel Technologies, Drug Delivery Solutions, and Clinical Supply Services. The Softgel Technologies segment offers formulation, development, and manufacturing services for softgels, which are used in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, and unit-dose cosmetics.

Insider Buying and Selling by Quarter for Catalent (NYSE:CTLT)

Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with's FREE daily email newsletter.

Leave a Reply